Enter Your Search:
Results 1-3 (3)
Go to page number:
Select a Filter Below
Pharmacology Research & Perspectives (1)
Vyas, Purvi (3)
Baghel, M. S. (1)
Bhoi, Bibhuti (1)
Chandola, H. M. (1)
Deole, Yogesh (1)
Ghanchi, Firoz (1)
Giri, Suresh R (1)
Jain, Mukul R (1)
Patel, Pankaj R (1)
Ranthem, Shivprakash (1)
Ranvir, Ramchandra (1)
Rath, Akshyaya (1)
Sisodia, Arvind (1)
Thakar, A. B. (1)
Trivedi, Chitrang (1)
Vanage, Geeta (1)
Year of Publication
Did you mean:
Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models
Jain, Mukul R
Giri, Suresh R
Patel, Pankaj R
Pharmacology Research & Perspectives
Saroglitazar is a novel nonthiazolidinediones (TZD) and nonfibric acid derivative designed to act as dual regulator of lipids and glucose metabolism by activating peroxisome proliferator-activated receptors (PPAR). These studies evaluate the efficacy and safety profile of Saroglitazar in preclinical in vitro and in vivo models. The EC50 values of Saroglitazar assessed in HepG2 cells using PPAR transactivation assay for hPPARα and hPPARγ were 0.65 pmol/L and 3 nmol/L, respectively. In db/db mice, 12-day treatment with Saroglitazar (0.01–3 mg/kg per day, orally) caused dose-dependent reductions in serum triglycerides (TG), free fatty acids (FFA), and glucose. The ED50 for these effects was found to be 0.05, 0.19, and 0.19 mg/kg, respectively with highly significant (91%) reduction in serum insulin and AUC-glucose following oral glucose administration (59%) at 1 mg/kg dose. Significant reduction in serum TG (upto 90%) was also observed in Zucker fa/fa rats, Swiss albino mice, and in high fat -high cholesterol (HF-HC)-fed Golden Syrian hamsters. LDL cholesterol was significantly lowered in hApoB100/hCETP double transgenic mice and HF-HC diet fed Golden Syrian Hamsters. Hyperinsulinemic-Euglycemic clamp study in Zucker fa/fa rats demonstrated potent insulin-sensitizing activity. Saroglitazar also showed a significant decrease in SBP (22 mmHg) and increase (62.1%) in serum adiponectin levels in Zucker fa/fa rats. A 90-day repeated dose comparative study in Wistar rats and marmosets confirmed efficacy (TG lowering) potential of Saroglitazar and has indicated low risk of PPAR-associated side effects in humans. Based on efficacy and safety profile, Saroglitazar appears to have good potential as novel therapeutic agent for treatment of dyslipidemia and diabetes.
Anti-diabetic; dual PPAR agonist; glitazar; hypertriglyceridemia; insulin sensitizer; lipaglyn
Clinical evaluation of Rasayana compound as an adjuvant in the management of tuberculosis with anti-Koch's treatment
Chandola, H. M.
Tuberculosis (TB) continues to intimidate the human race since time immemorial not only due to its effects as a medical malady, but also by its impact as a social and economic tragedy. At the dawn of the new millennium, we are still mute witnesses to the silent yet efficient march of this sagacious disease, its myriad manifestations and above all its unequalled, vicious power. Through the millennia, TB never ever disappeared from the developing world. In 1991, the World Health Assembly (WHA) resolution recognized TB as a major global public health problem. The DOTS strategy was launched in 1994, and became the global recommended strategy for TB control since then. The present study deals with clinical evaluation of Rasayana drugs considering of Amalaki (Emblica officinalis Gaertn.), Guduchi (Tinospora cordifolia willd.), Ashwagandha (Withania somnifera L.) Dunal, Yastimadhu (Glycyrrhiza glabra Linn.), Pippali (Piper longum Linn.), Sariva (Hemidesmus indicus R.Br.), Kustha (Saussurea lappa Falc.), Haridra (Curcuma longa Linn.) and Kulinjan (Alpinia galangal Linn.) as an adjuvant therapy with anti-Koch's treatment. The results obtained revealed that Rasayana compound was found to decrease cough (83%), fever (93%), dyspnea (71.3%), hemoptysis (87%) and increase body weight (7.7%) with statistically highly significant (P<0.001).
Anti-Koch's treatment; DOTS; Rasayana; tuberculosis
Efficacy of Rasayana Avaleha as adjuvant to radiotherapy and chemotherapy in reducing adverse effects
Thakar, A. B.
Baghel, M. S.
Cancer is the most dreadful disease affecting mankind. The available treatments such as chemotherapy and radiotherapy have cytotoxic effects, which are hazardous to the normal cells of the patient, causing many unnecessary effects. This further leads to complications of the therapy, impaired health, and deterioration of quality of life, resulting in mandatory stoppage of the treatment. In the present study, the efficacy of an Ayurvedic formulation, Rasayana Avaleha, has been evaluated as an adjuvant medication to modern radiotherapy and chemotherapy. A total of 36 cancer patients were registered in this trial and were divided into two groups, group A and group B. In group A, the patients were treated with radiotherapy and chemotherapy along with adjuvant Rasayana Avaleha (RT + CT + RA), while in group B only radiotherapy and chemotherapy (RT + CT) were given, as the control group. After assessing the results, it was observed that Rasayana Avaleha gave better results in controlling the adverse effect of chemotherapy and radiotherapy in comparison with the control group. Therefore, Rasayana Avaleha has proved to be an effective adjuvant therapy in protecting patients from the adverse effects of chemotherapy and radiotherapy.
Cancer; Radiotherapy; Chemotherapy; Adverse Effects; Ayurveda; Rasayana Avaleha
Results 1-3 (3)
Go to page number:
Remove citation from clipboard
Add citation to clipboard
This will clear all selections from your clipboard. Do you wish proceed?
Clipboard is full! Please remove an item and try again.
PubMed Central Canada is a service of the
Canadian Institutes of Health Research
(CIHR) working in partnership with the National Research Council's
national science library
in cooperation with the
National Center for Biotechnology Information
U.S. National Library of Medicine
(NCBI/NLM). It includes content provided to the
PubMed Central International archive
by participating publishers.